MCID: TST014
MIFTS: 52

Testicular Cancer

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Testicular Cancer

MalaCards integrated aliases for Testicular Cancer:

Name: Testicular Cancer 11 53 5 41 14 75 33
Malignant Neoplasm of Testis 71 31
Testicular Carcinoma 53 16
Testicular Neoplasms 43 71
Testis Cancer 11 33
Malignant Neoplasm of Testis, Unspecified 33
Testicular Malignant Germ Cell Tumor 71
Primary Malignant Neoplasm of Testis 33
Malignant Neoplasm of Testis, Nos 33
Childhood Neoplasm of the Testis 11
Pediatric Testicular Neoplasm 11
Childhood Testicular Neoplasm 71
Malignant Tumour of Testis 33
Carcinoma of the Testis 71
Testicular Neoplasm 16
Neoplasm of Testis 11
Testicular Tumors 14
Testicular Tumor 11
Cancer of Testis 33
Testis Neoplasm 11
Testicle Cancer 33

Classifications:



External Ids:

Disease Ontology 11 DOID:2998
ICD9CM 34 186
MeSH 43 D013736
SNOMED-CT 68 126900000 94087009
ICD10 31 C62 C62.9
UMLS 71 C0039590 C0153594 C0677483 more

Summaries for Testicular Cancer

MedlinePlus: 41 Testicles, or testes, make male hormones and sperm. They are two egg-shaped organs inside the scrotum, the loose sac of skin behind the penis. You can get cancer in one or both testicles. Testicular cancer mainly affects young men between the ages of 20 and 39. It is also more common in men who: Have had abnormal testicle development Have had an undescended testicle Have a family history of the cancer Symptoms include pain, swelling, or lumps in your testicles or groin area. Doctors use a physical exam, lab tests, imaging tests, and a biopsy to diagnose testicular cancer. Most cases can be treated, especially if found early. Treatment options include surgery, radiation, and/or chemotherapy. Regular exams after treatment are important. Treatments may also cause infertility. If you may want children later on, you should consider sperm banking before treatment. NIH: National Cancer Institute

MalaCards based summary: Testicular Cancer, also known as malignant neoplasm of testis, is related to cryptorchidism, unilateral or bilateral and testicular germ cell cancer. An important gene associated with Testicular Cancer is STK11 (Serine/Threonine Kinase 11), and among its related pathways/superpathways is Relaxin receptors. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include testicles, testis and lymph node, and related phenotypes are neoplasm and endocrine/exocrine gland

Disease Ontology: 11 A male reproductive system cancer that is located in the testicles.

Wikipedia: 75 Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system.... more...

Related Diseases for Testicular Cancer

Diseases related to Testicular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 682)
# Related Disease Score Top Affiliating Genes
1 cryptorchidism, unilateral or bilateral 32.5 SHBG RXFP2 INSL3 CGB5 ALPP AFP
2 testicular germ cell cancer 32.4 XIST STK11 MAGEA4 INSL3 FGFR3 BCL10
3 testicular germ cell tumor 32.3 STK11 FGFR3 BCL10
4 testicular disease 32.3 SHBG RXFP2 MAGEA4 INSL3 ERCC1 AFP
5 spermatocytoma 32.2 MAGEA4 FGFR3 AFP
6 seminoma 32.2 TDRG1 MAGEA4 CGB5 ALPP AFP
7 germ cell tumor 32.0 STK11 FGFR3
8 endodermal sinus tumor 31.4 CGB5 ALPP AFP
9 inguinal hernia 31.2 RXFP2 INSL3 AFP
10 extragonadal germ cell cancer 30.9 CGB5 AFP
11 androgen insensitivity syndrome 30.8 SHBG RXFP2 INSL3
12 male infertility 30.8 SHBG RXFP2 INSL3 CCNA1
13 testicular torsion 30.7 SHBG RXFP2 INSL3 AFP
14 gastric cancer 30.7 XIST TDRG1 STK11 ERCC1 DNMT1 CTAG1B
15 hypogonadotropic hypogonadism 30.6 XIST SHBG RXFP2 INSL3
16 germinoma 30.5 CGB5 ALPP AFP
17 disorder of sexual development 30.3 SHBG RXFP2 INSL3 AFP
18 sertoli-leydig cell tumor 30.3 INSL3 ALPP AFP
19 gonadoblastoma 30.3 CGB5 ALPP AFP
20 adenomatoid tumor 30.3 CGB5 AFP
21 premature menopause 29.8 SHBG INSL3 ERCC1 AFP
22 rete testis neoplasm 11.3
23 embryonal carcinoma 11.2
24 testicular leydig cell tumor 11.2
25 testis sarcoma 11.1
26 rete testis adenocarcinoma 11.1
27 testis refractory cancer 11.0
28 isolated splenogonadal fusion 11.0
29 persistent mullerian duct syndrome 11.0
30 spermatocele 11.0
31 testicular brenner tumor 11.0
32 germ cell cancer 10.9
33 teratoma 10.9
34 nonseminomatous germ cell tumor 10.8
35 pigmented villonodular synovitis 10.7
36 tenosynovial giant cell tumor 10.7
37 mature teratoma 10.6
38 testicular germ cell tumor 1 10.6
39 infertility 10.6
40 hypogonadism 10.6
41 choriocarcinoma 10.5
42 azoospermia 10.5
43 impotence 10.5
44 testicular seminoma 10.5
45 testicular microlithiasis 10.5
46 corpus luteum cyst 10.4 CGB5 AFP
47 microinvasive gastric cancer 10.4 XIST TDRG1 AFP
48 hepatic tuberculosis 10.4 ALPP AFP
49 lymphoma, hodgkin, classic 10.4
50 raynaud disease 10.4

Graphical network of the top 20 diseases related to Testicular Cancer:



Diseases related to Testicular Cancer

Symptoms & Phenotypes for Testicular Cancer

MGI Mouse Phenotypes related to Testicular Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.7 AFP DNMT1 ERCC1 FGFR3 IGF2BP2 RXFP2
2 endocrine/exocrine gland MP:0005379 9.61 AFP BCL10 CCNA1 CGB5 ERCC1 INSL3
3 reproductive system MP:0005389 9.32 AFP CCNA1 CGB5 DNMT1 ERCC1 FGFR3

Drugs & Therapeutics for Testicular Cancer

Drugs for Testicular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
5
Ondansetron Approved, Withdrawn Phase 3 99614-02-5 4595
6
Fosaprepitant Approved Phase 3 172673-20-0 219090 135413538
7
Olanzapine Approved, Investigational Phase 3 132539-06-1 135398745 4585
8
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
9
Etoposide Approved Phase 3 33419-42-0 36462
10
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
11
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
12
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Vinblastine Approved Phase 3 865-21-4 241903 13342
15
Palifosfamide Investigational Phase 3 31645-39-3 100427
16 Hormones Phase 3
17 Immunosuppressive Agents Phase 3
18 Immunologic Factors Phase 3
19 Calcium, Dietary Phase 3
20 Antirheumatic Agents Phase 3
21 Neurotransmitter Agents Phase 3
22 Antipsychotic Agents Phase 3
23 Psychotropic Drugs Phase 3
24 Antiemetics Phase 3
25 Serotonin Uptake Inhibitors Phase 3
26 Gastrointestinal Agents Phase 3
27 Anti-Bacterial Agents Phase 3
28
Etoposide phosphate Phase 3 16760419
29 Antibiotics, Antitubercular Phase 3
30 Albumin-Bound Paclitaxel Phase 3
31 Antimitotic Agents Phase 3
32 Tubulin Modulators Phase 3
33 Alkylating Agents Phase 3
34 Antineoplastic Agents, Alkylating Phase 3
35
Calcium Nutraceutical Phase 3 7440-70-2 271
36
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
38
Magnesium sulfate Approved, Investigational, Vet_approved Phase 1, Phase 2 7487-88-9
39
Ranitidine Approved, Withdrawn Phase 1, Phase 2 66357-59-3, 82530-72-1, 66357-35-5 3001055 5039
40
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
41
Chlorpheniramine Approved Phase 1, Phase 2 113-92-8, 132-22-9 2725
42
Sorbitol Approved, Investigational Phase 1, Phase 2 69-65-8, 50-70-4 453 6251 5780
43
Pancrelipase Approved, Investigational Phase 2 53608-75-6 8519
44
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
45
Tremelimumab Approved, Investigational Phase 1, Phase 2 745013-59-6
46
Lorazepam Approved Phase 2 846-49-1 3958
47
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
48
Fluorouracil Approved Phase 2 51-21-8 3385
49
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
50
Epirubicin Approved Phase 2 56420-45-2 41867

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy Completed NCT01641172 Phase 4
2 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Unknown status NCT01726374 Phase 3 BEP(500)
3 A Randomized Double-blind Study of Testosterone Replacement Therapy or Placebo in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency (Einstein-intervention) Completed NCT02991209 Phase 2, Phase 3 Testosterone;Placebos
4 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
5 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
6 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
7 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
8 A Phase III Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Receiving 5-day Cisplatin Combination Chemotherapy Recruiting NCT05244577 Phase 3 Olanzapine Tablets;Placebo
9 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
10 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
11 A Biobehavioral Intervention for Young Men With Testicular Cancer: A Pilot Study Unknown status NCT04150848 Phase 2
12 Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
13 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
14 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
15 A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
16 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
17 A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor Completed NCT01684098 Phase 2 Tc 99m EC20
18 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist Poly-ICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly-ICLC
19 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
20 A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Completed NCT00183820 Phase 2 paclitaxel, gemcitabine, and oxaliplatin
21 A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors Completed NCT00957905 Phase 2 Alvocidib Hydrochloride;Fluorouracil;Leucovorin Calcium;Oxaliplatin
22 A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer Completed NCT01242631 Phase 2 Everolimus
23 Phase II Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer Completed NCT02860819 Phase 2 Veliparib;Gemcitabine;Carboplatin
24 Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation Completed NCT00231582 Phase 2 epirubicin;paclitaxel;etoposide;ifosfamide;carboplatin
25 Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
26 A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence Completed NCT00123773 Phase 2
27 Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors Completed NCT02161692 Phase 2 Cyclophosphamide;Etoposide;Cisplatin;Bleomycin;Carboplatin
28 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
29 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
30 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
31 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
32 High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
33 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
34 Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors Completed NCT00006043 Phase 2 temozolomide
35 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
36 Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
37 Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors Completed NCT00003518 Phase 2 gemcitabine hydrochloride;paclitaxel
38 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
39 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
40 Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer. Completed NCT01466231 Phase 2 Everolimus
41 Short-term Testosterone Replacement in Testicular Cancer Survivors to Treat Overweight and Improve Cardiometabolic Risk: A Pilot Study Recruiting NCT03339635 Phase 2 Androgel (Testosterone gel);Placebo gel
42 Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Recruiting NCT02478502 Phase 2 cabazitaxel
43 Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts Recruiting NCT03937843 Phase 2 Carboplatin;Cisplatin;Etoposide
44 Reduced-dose Radiotherapy Following High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Central Nervous System Non-germinomatous Germ Cell Tumors Recruiting NCT02784054 Phase 2 Carboplatin;Etoposide;Cyclophosphamide;Bleomycin;Thiotepa;Melphalan
45 Phase I/IIa Trial to Evaluate Safety and Preliminary Efficacy of CLDN6-CAR-NK in Patients With CLDN6-positive Advanced Solid Tumors Recruiting NCT05410717 Phase 1, Phase 2
46 High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors Active, not recruiting NCT00936936 Phase 2 Gemcitabine;Docetaxel;Melphalan;Carboplatin;Mesna;Ifosfamide;Etoposide
47 Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT) Not yet recruiting NCT05634785 Phase 2 Cyclophosphamid;Fludarabine
48 Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer Terminated NCT00531687 Phase 2 Paclitaxel;Cisplatin;Gemcitabine
49 A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Terminated NCT02689219 Phase 2 Brentuximab Vedotin
50 A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206 Terminated NCT02499952 Phase 2 Pembrolizumab

Search NIH Clinical Center for Testicular Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Methotrexate
Methotrexate Sodium
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: testicular neoplasms

Genetic Tests for Testicular Cancer

Anatomical Context for Testicular Cancer

Organs/tissues related to Testicular Cancer:

FMA: Testicles
MalaCards : Testis, Lymph Node, Testes, Skin, Bone Marrow, Bone, Skeletal Muscle

Publications for Testicular Cancer

Articles related to Testicular Cancer:

(show top 50) (show all 11234)
# Title Authors PMID Year
1
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. 53 62 5
9887330 1999
2
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. 53 62 5
9605748 1998
3
Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas. 5
10582682 1999
4
Long-term results of postoperative unsuspected small cell lung cancer on real-world data. 41
36461029 2022
5
Surveillance Strategy after Curative Resection for Oesophageal Squamous Cell Cancer Using the Hazard Function. 41
36457081 2022
6
Long-Term Oncologic Outcome of Breast Cancer in Southern Iran: A Retrospective Cohort Study. 41
36444601 2022
7
Seminal expression of NY-ESO-1 and MAGE-A4 as markers for the testicular cancer. 53 62
19207618 2009
8
Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein. 53 62
19493258 2009
9
Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. 53 62
18440530 2009
10
Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. 53 62
18787014 2008
11
[Place of serum HCG assay in the follow-up of non-HCG-secreting testicular seminomas]. 53 62
18971108 2008
12
False tumor marker surge evoked by peripheral blood stem cell transplantation. 53 62
18515737 2008
13
The use of tumor markers in testis cancer in the United States: a potential quality issue. 53 62
18312934 2008
14
Late relapse of testicular cancer 21 years after first complete remission: a case report. 53 62
18260359 2008
15
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. 53 62
16960727 2007
16
Immunostaining for placental alkaline phosphatase on fine-needle aspiration specimens to detect noninvasive testicular cancer: a prospective evaluation in cryptorchid men. 53 62
17227503 2007
17
[Significance of thcg assay in the management of testicular cancer--the possibility of a standard assay in testicular cancer as an alternative to FbetahCG assay]. 53 62
17302291 2007
18
Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. 53 62
16687567 2006
19
Y chromosome instability in testicular cancer. 53 62
16483836 2006
20
Immunostaining for placental alkaline phosphatase on fine-needle aspiration specimens to detect noninvasive testicular cancer: a prospective evaluation in cryptorchid men. 53 62
16643476 2006
21
[Two cases of testicular cancer with low human chorionic gonadotropin (hCG) levels after treatment]. 53 62
16119815 2005
22
Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer. 53 62
15885892 2005
23
Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-testosterone axis. 53 62
15755855 2005
24
Human tissue kallikrein gene family: applications in cancer. 53 62
15911097 2005
25
Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. 53 62
15685234 2005
26
Ethnic variation in the prevalence of AZF deletions in testicular cancer. 53 62
15450403 2004
27
Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. 53 62
15305826 2004
28
Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer. 53 62
15242364 2004
29
[Significance of current bio- and molecular-markers in urological cancers]. 53 62
15272577 2004
30
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. 53 62
14723995 2004
31
Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. 53 62
14668798 2003
32
[Paraneoplastic hyperthyroidism in a patient with metastasizing teratocarcinoma and excessively high HCG]. 53 62
14579189 2003
33
E- and A-type cyclins as markers for cancer diagnosis and prognosis. 53 62
14510182 2003
34
No AZF deletion in 160 patients with testicular germ cell neoplasia. 53 62
12900510 2003
35
[Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer]. 53 62
12910930 2003
36
Double immunolabeling by the RBM and the PLAP markers for identifying intratubular (in situ) germ cell neoplasia of the testis. 53 62
12598912 2003
37
Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. 53 62
12483540 2002
38
alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer. 53 62
11856111 2002
39
[Lung resistance protein analysis in testicular cancer]. 53 62
12563357 2002
40
[A prospect of molecular biology in the field of urologic oncology: mechanisms of carcinogenesis or tumor development in testicular cancer]. 53 62
11771175 2001
41
PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis. 53 62
11762823 2001
42
Establishment of a testicular carcinoma cell line producing alpha-fetoprotein. 53 62
11678760 2001
43
Organization and chromosomal localization of the murine Testisin gene encoding a serine protease temporally expressed during spermatogenesis. 53 62
11231276 2001
44
A new highly specific monoclonal antibody against placental alkaline phosphatase: a potential marker for the early detection of testis tumour. 53 62
11069419 2000
45
Localization, expression and genomic structure of the gene encoding the human serine protease testisin. 53 62
11004480 2000
46
Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans. 53 62
10408403 1999
47
125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. 53 62
10408402 1999
48
Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. 53 62
10071288 1999
49
Standardization and potential use of HPLC for detection of cellular placental alkaline phosphatase using established tumour cell lines and fresh tumour biopsies. 53 62
10743701 1999
50
Gonadotrophin secretion patterns in testicular cancer patients with greatly increased human chorionic gonadotrophin serum concentrations. 53 62
9834462 1998

Variations for Testicular Cancer

ClinVar genetic disease variations for Testicular Cancer:

5 (show all 30)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 STK11 NM_000455.5(STK11):c.488G>A (p.Gly163Asp) SNV Pathogenic
7448 rs137853078 GRCh37: 19:1220395-1220395
GRCh38: 19:1220396-1220396
2 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic
16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
3 FGFR3 NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic
16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
4 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic
16340 rs4647924 GRCh37: 4:1803571-1803571
GRCh38: 4:1801844-1801844
5 FGFR3 NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg) SNV Pathogenic
16327 rs28931614 GRCh37: 4:1806119-1806119
GRCh38: 4:1804392-1804392
6 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic
16338 rs28933068 GRCh37: 4:1807371-1807371
GRCh38: 4:1805644-1805644
7 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic
65855 rs121913105 GRCh37: 4:1807890-1807890
GRCh38: 4:1806163-1806163
8 BCL10 NM_003921.5(BCL10):c.488C>T (p.Thr163Met) SNV Pathogenic
30361 rs370432633 GRCh37: 1:85733524-85733524
GRCh38: 1:85267841-85267841
9 STK11 NM_000455.5(STK11):c.719C>G (p.Ser240Trp) SNV Likely Pathogenic
182902 rs730881976 GRCh37: 19:1220701-1220701
GRCh38: 19:1220702-1220702
10 STK11 NM_000455.5(STK11):c.1012G>A (p.Val338Met) SNV Uncertain Significance
142198 rs587782302 GRCh37: 19:1223075-1223075
GRCh38: 19:1223076-1223076
11 STK11 NM_000455.5(STK11):c.1195C>A (p.Gln399Lys) SNV Uncertain Significance
403791 rs1060499968 GRCh37: 19:1226539-1226539
GRCh38: 19:1226540-1226540
12 STK11 NM_000455.5(STK11):c.1243C>G (p.Arg415Gly) SNV Uncertain Significance
220264 rs864622448 GRCh37: 19:1226587-1226587
GRCh38: 19:1226588-1226588
13 FGFR3 NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser) SNV Uncertain Significance
465350 rs764892330 GRCh37: 4:1808017-1808017
GRCh38: 4:1806290-1806290
14 KIT NM_000222.3(KIT):c.101C>T (p.Pro34Leu) SNV Uncertain Significance
409788 rs55755457 GRCh37: 4:55561711-55561711
GRCh38: 4:54695545-54695545
15 KIT NM_000222.3(KIT):c.1553C>T (p.Pro518Leu) SNV Uncertain Significance
237245 rs569408054 GRCh37: 4:55593396-55593396
GRCh38: 4:54727230-54727230
16 KIT NM_000222.3(KIT):c.302A>G (p.His101Arg) SNV Uncertain Significance
458940 rs1274601103 GRCh37: 4:55561912-55561912
GRCh38: 4:54695746-54695746
17 KIT NM_000222.3(KIT):c.200C>G (p.Thr67Ser) SNV Uncertain Significance
237252 rs144933028 GRCh37: 4:55561810-55561810
GRCh38: 4:54695644-54695644
18 KIT NM_000222.3(KIT):c.2900C>G (p.Ser967Cys) SNV Uncertain Significance
458936 rs1232060384 GRCh37: 4:55604692-55604692
GRCh38: 4:54738526-54738526
19 KIT NM_000222.3(KIT):c.2887A>G (p.Thr963Ala) SNV Uncertain Significance
409774 rs773709702 GRCh37: 4:55604679-55604679
GRCh38: 4:54738513-54738513
20 KIT NM_000222.3(KIT):c.2294A>G (p.Asp765Gly) SNV Uncertain Significance
409730 rs1060502545 GRCh37: 4:55598097-55598097
GRCh38: 4:54731931-54731931
21 STK11 NM_000455.5(STK11):c.632G>A (p.Arg211Gln) SNV Uncertain Significance
182910 rs730881982 GRCh37: 19:1220614-1220614
GRCh38: 19:1220615-1220615
22 STK11 NM_000455.5(STK11):c.566C>T (p.Thr189Ile) SNV Uncertain Significance
141128 rs587781515 GRCh37: 19:1220473-1220473
GRCh38: 19:1220474-1220474
23 STK11 NM_000455.5(STK11):c.464+5G>A SNV Uncertain Significance
141354 rs587781681 GRCh37: 19:1219417-1219417
GRCh38: 19:1219418-1219418
24 KIT NM_000222.3(KIT):c.2881G>A (p.Gly961Ser) SNV Uncertain Significance
237271 rs773828910 GRCh37: 4:55604673-55604673
GRCh38: 4:54738507-54738507
25 KIT NM_000222.3(KIT):c.2836C>T (p.Arg946Ter) SNV Uncertain Significance
576610 rs139000082 GRCh37: 4:55604628-55604628
GRCh38: 4:54738462-54738462
26 KIT NM_000222.3(KIT):c.2104C>G (p.Leu702Val) SNV Uncertain Significance
409779 rs768847037 GRCh37: 4:55595614-55595614
GRCh38: 4:54729448-54729448
27 KIT NM_000222.3(KIT):c.2057G>A (p.Arg686His) SNV Uncertain Significance
458902 rs143772138 GRCh37: 4:55595567-55595567
GRCh38: 4:54729401-54729401
28 KIT NM_000222.3(KIT):c.2863G>T (p.Val955Leu) SNV Uncertain Significance
409783 rs1060502568 GRCh37: 4:55604655-55604655
GRCh38: 4:54738489-54738489
29 FGFR3 NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp) SNV Uncertain Significance
546226 rs369232922 GRCh37: 4:1801071-1801071
GRCh38: 4:1799344-1799344
30 FGFR3 NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser) SNV Uncertain Significance
521225 rs139773438 GRCh37: 4:1808395-1808395
GRCh38: 4:1806668-1806668

Copy number variations for Testicular Cancer from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 61546 12 1 35400000 Gain Testicular cancer
2 202070 5 76900000 102800000 Loss Testicular cancer
3 217038 7 1 158821424 Gain Testicular cancer
4 237464 8 23300000 146274826 Gain Testicular cancer
5 262544 X 37500000 154913754 Gain Testicular cancer
6 262545 X 37500000 154913754 Gain Testicular cancer
7 266960 Y 174481503 174538309 Deletion AZF1 Testicular cancer

Expression for Testicular Cancer

Search GEO for disease gene expression data for Testicular Cancer.

Pathways for Testicular Cancer

Pathways related to Testicular Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.53 RXFP2 INSL3

GO Terms for Testicular Cancer

Sources for Testicular Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....